1. Home
  2. INCY vs WWD Comparison

INCY vs WWD Comparison

Compare INCY & WWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INCY
  • WWD
  • Stock Information
  • Founded
  • INCY 1991
  • WWD 1870
  • Country
  • INCY United States
  • WWD United States
  • Employees
  • INCY N/A
  • WWD N/A
  • Industry
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • WWD Industrial Machinery/Components
  • Sector
  • INCY Health Care
  • WWD Energy
  • Exchange
  • INCY Nasdaq
  • WWD Nasdaq
  • Market Cap
  • INCY 13.4B
  • WWD 10.8B
  • IPO Year
  • INCY 1993
  • WWD N/A
  • Fundamental
  • Price
  • INCY $58.98
  • WWD $196.49
  • Analyst Decision
  • INCY Hold
  • WWD Buy
  • Analyst Count
  • INCY 20
  • WWD 8
  • Target Price
  • INCY $73.06
  • WWD $191.88
  • AVG Volume (30 Days)
  • INCY 1.8M
  • WWD 490.2K
  • Earning Date
  • INCY 04-29-2025
  • WWD 04-28-2025
  • Dividend Yield
  • INCY N/A
  • WWD 0.57%
  • EPS Growth
  • INCY N/A
  • WWD 8.19
  • EPS
  • INCY 0.10
  • WWD 6.19
  • Revenue
  • INCY $4,413,226,000.00
  • WWD $3,358,530,000.00
  • Revenue This Year
  • INCY $12.28
  • WWD $3.45
  • Revenue Next Year
  • INCY $9.20
  • WWD $8.61
  • P/E Ratio
  • INCY $611.49
  • WWD $31.67
  • Revenue Growth
  • INCY 17.13
  • WWD 4.96
  • 52 Week Low
  • INCY $52.81
  • WWD $145.98
  • 52 Week High
  • INCY $83.95
  • WWD $201.64
  • Technical
  • Relative Strength Index (RSI)
  • INCY 44.09
  • WWD 65.96
  • Support Level
  • INCY $57.77
  • WWD $190.51
  • Resistance Level
  • INCY $62.87
  • WWD $197.00
  • Average True Range (ATR)
  • INCY 1.78
  • WWD 5.46
  • MACD
  • INCY 0.20
  • WWD 2.09
  • Stochastic Oscillator
  • INCY 36.23
  • WWD 92.81

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About WWD Woodward Inc.

Woodward Inc is an independent designer, manufacturer, and service provider of control solutions for the aerospace and industrial markets. It designs, produces, and services reliable, efficient, low-emission, and high-performance energy control products for diverse applications in challenging environments. The company operates in two segments, Aerospace and Industrial. The Aerospace segment provides fuel pumps, actuators, air valves, specialty valves, fuel nozzles, and thrust reverser actuation systems for turbine engines and nacelles, and flight deck controls, actuators, servo controls, motors, and sensors for aircraft. The Industrial segment offers actuators, valves, pumps, fuel injection systems, solenoids, ignition systems, speed controls, electronics and software, and sensors.

Share on Social Networks: